Lorenzi M, et al. - Researchers evaluate the efficacy of adding ezetimibe to simvastatin, atorvastatin, or rosuvastatin monotherapy vs doubling the dosage or switching to a higher-potency statin in a population of patients with hypocholesterolemia at high risk of cardiovascular disease (CVD) and who had been previously treated with a statin. They performed a systematic literature search and established evidence bases for populations of atorvastatin-, simvastatin-, and rosuvastatin-experienced patients using eligible randomized controlled trials. They observed that patients at high risk for CVD had a greater reduction in low-density lipoprotein cholesterol in correlation with ezetimibe addition to ongoing simvastatin, atorvastatin, or rosuvastatin monotherapy vs doubling the initial statin dose.